2024/05/01 by Kathryn Hoffmann, Astrid Hainzl, Michael Stingl +35 · 3 voices · 28 citations
Medicine · Neuroscience · #Amyotrophic Lateral Sclerosis Research #Fibromyalgia and Chronic Fatigue Syndrome Research #Gynecology #Medicine #Olfactory and Sensory Function Studies
paper · pdf · doi:10.1007/s00508-024-02372-y
published in Wiener klinische Wochenschrift 136(S5), 103-123 (Springer Science+Business Media)
openalex publication_date 2024/05/01 · openalex created_date 2024/05/15 · openalex updated_date 2026/07/30
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe, chronic multisystemic disease which, depending on its severity, can lead to considerable physical and cognitive impairment, loss of ability to work and the need for nursing care including artificial nutrition and, in very severe cases, even death.The aim of this D-A-CH (Germany, Austria, Switzerland) consensus statement is 1) to summarize the current state of knowledge on ME/CFS, 2) to highlight the Canadian Consensus Criteria (CCC) as clinical criteria for diagnostics with a focus on the leading symptom post-exertional malaise (PEM) and 3) to provide an overview of current options and possible future developments, particularly with regard to diagnostics and therapy. The D-A-CH consensus statement is intended to support physicians, therapists and valuer in diagnosing patients with suspected ME/CFS by means of adequate anamnesis and clinical-physical examinations as well as the recommended clinical CCC, using the questionnaires and other examination methods presented. The overview of the two pillars of therapy for ME/CFS, pacing and symptom-relieving therapy options, is intended not only to provide orientation for physicians and therapists, but also to support decision-makers from healthcare policy and insurance companies in determining which therapy options should already be reimbursable by them at this point in time for the indication ME/CFS.